Intraarticular injection of heparin-binding insulin-like growth factor 1 sustains delivery of insulin-like growth factor 1 to cartilage through binding to chondroitin sulfate

Arthritis Care and Research

Volumn 62, Issue 12, 2010, Pages 3686-3694

  Miller, Rachel E ^a   Grodzinsky, Alan J ^a   Cummings, Kiersten ^b   Plaas, Anna H K ^c   Cole, Ada A ^c   Lee, Richard T ^b   Patwari, Parth ^b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULFATE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN BINDING INSULIN LIKE GROWTH FACTOR 1; HYBRID PROTEIN; SOMATOMEDIN C; UNCLASSIFIED DRUG; HEPARIN BINDING PROTEIN; N ACETYLGALACTOSAMINE 4 SULFATASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; BINDING AFFINITY; BINDING ASSAY; CONTROLLED STUDY; DRUG BINDING; DRUG ISOLATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLANT; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; KNEE MENISCUS; MALE; MONOLAYER CULTURE; NONHUMAN; RAT; SURFACE PLASMON RESONANCE; TENDON; WESTERN BLOTTING; CARTILAGE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RETENTION; ENZYMATIC ASSAY; HEPARINIZATION; KNEE; PRIORITY JOURNAL; PROTEIN BINDING;

ANIMALS; CARTILAGE, ARTICULAR; CATTLE; CELLS, CULTURED; CHONDROITIN SULFATES; CHONDROITINASES AND CHONDROITIN LYASES; HEPARIN; HEPARITIN SULFATE; INJECTIONS, INTRA-ARTICULAR; INSULIN-LIKE GROWTH FACTOR I; MODELS, ANIMAL; POLYSACCHARIDE-LYASES;

EID: 78650063775     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27709     Document Type: Article

References (51)

1. Goldring MB,. Update on the biology of the chondrocyte and new approaches to treating cartilage diseases. Best Pract Res Clin Rheumatol 2006; 20: 1003-25.
2. Bonassar LJ, Grodzinsky AJ, Frank EH, Davila SG, Bhaktav NR, Trippel SB,. The effect of dynamic compression on the response of articular cartilage to insulin-like growth factor-I. J Orthop Res 2001; 19: 11-7.
3. McQuillan DJ, Handley CJ, Campbell MA, Bolis S, Milway VE, Herinton AC,. Stimulation of proteoglycan biosynthesis by serum and insulin-like growth factor-I in cultured bovine articular cartilage. Biochem J 1986; 240: 423-30.
4. Curtis AJ, Devenish RJ, Handley CJ,. Modulation of aggrecan and link-protein synthesis in articular cartilage. Biochem J 1992; 288: 721-6.
5. Hui W, Rowan AD, Cawston T,. Modulation of the expression of matrix metalloproteinase and tissue inhibitors of metalloproteinases by TGF-β1 and IGF-1 in primary human articular and bovine nasal chondrocytes stimulated with TNF-α. Cytokine 2001; 16: 31-5.
6. Luyten FP, Hascall VC, Nissley SP, Morales TI, Reddi AH,. Insulin-like growth factors maintain steady-state metabolism of proteoglycans in bovine articular cartilage explants. Arch Biochem Biophys 1988; 267: 416-25.
7. Tyler JA,. Insulin-like growth factor I can decrease degradation and promote synthesis of proteoglycan in cartilage exposed to cytokines. Biochem J 1989; 260: 543-8.
8. Schneiderman R, Rosenberg N, Hiss J, Lee P, Liu F, Hintz RL, et al. Concentration and size distribution of insulin-like growth factor-1 in human normal and osteoarthritic synovial fluid and cartilage. Arch Biochem Biophys 1995; 324: 173-88.
9. Schmidt MB, Chen EH, Lynch SE,. A review of the effects of insulin-like growth factor and platelet derived growth factor on in vivo cartilage healing and repair. Osteoarthritis Cartilage 2006; 14: 403-12.
10. Matsumoto T, Gargosky SE, Iwasaki K, Rosenfeld RG,. Identification and characterization of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP proteases in human synovial fluid. J Clin Endocrinol Metab 1996; 81: 150-5.
11. Loeser RF, Shanker G,. Autocrine stimulation by insulin-like growth factor 1 and insulin-like growth factor 2 mediates chondrocyte survival in vitro. Arthritis Rheum 2000; 43: 1552-9.
12. Nixon A, Saxer R, Brower-Toland BD,. Exogenous insulin-like growth factor-I stimulates an autoinductive IGF-I autocrine/paracrine response in chondrocytes. J Orthop Res 2001; 19: 26-32.
13. Madry H, Kaul G, Cucchiarini M, Stein U, Zurakowski D, Remberger K, et al. Enhanced repair of articular cartilage defects in vivo by transplanted chondrocytes overexpressing insulin-like growth factor I (IGF-I). Gene Ther 2005; 12: 1171-9.
14. Goodrich LR, Hidaka C, Robbins PD, Evans CH, Nixon AJ,. Genetic modification of chondrocytes with insulin-like growth factor-1 enhances cartilage healing in an equine model. J Bone Joint Surg Br 2007; 89: 672-85.
15. Laron Z,. Somatomedin-1 (recombinant insulin-like growth factor-1): clinical pharmacology and potential treatment of endocrine and metabolic disorders. BioDrugs 1999; 11: 55-70.
16. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563-6.
17. Jabri N, Schalch D, Schwartz S, Fischer J, Kipnes M, Radnik B, et al. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes 1994; 43: 369-74.
18. Fortier LA, Mohammed HO, Lust G, Nixon AJ,. Insulin-like growth factor-I enhances cell-based repair of articular cartilage. J Bone Joint Surg Br 2002; 84: 276-88.
19. Nixon AJ, Fortier LA, Williams J, Mohammed H,. Enhanced repair of extensive articular defects by insulin-like growth factor-I-laden fibrin composites. J Orthop Res 1999; 17: 475-87.
20. Hunziker EB, Rosenberg LC,. Repair of partial-thickness defects in articular cartilage: cell recruitment from the synovial membrane. J Bone Joint Surg Am 1996; 78: 721-33.
21. Farach-Carson MC, Hecht JT, Carson DD,. Heparan sulfate proteoglycans: key players in cartilage biology. Crit Rev Eukaryot Gene Expr 2005; 15: 29-48.
22. Kirn-Safran CB, Gomes RR, Brown AJ, Carson DD,. Heparan sulfate proteoglycans: coordinators of multiple signaling pathways during chondrogenesis. Birth Defects Res C Embryo Today 2004; 72: 69-88.
23. Heinegard D,. Proteoglycans and more-from molecules to biology. Int J Exp Pathol 2009; 90: 575-86.
24. Govindraj P, West L, Smith S, Hassell JR,. Modulation of FGF-2 binding to chondrocytes from the developing growth plate by perlecan. Matrix Biol 2006; 25: 232-9.
25. Vincent TL, McLean CJ, Full LE, Peston D, Saklatvala J,. FGF-2 is bound to perlecan in the pericellular matrix of articular cartilage, where it acts as a chondrocyte mechanotransducer. Osteoarthritis Cartilage 2007; 15: 752-63.
26. Vincent T, Hermansson M, Bolton M, Wait R, Saklatvala J,. Basic FGF mediates an immediate response of articular cartilage to mechanical injury. Proc Natl Acad Sci U S A 2002; 99: 8259-64.
27. Vincent TL, Hermansson MA, Hansen UN, Amis AA, Saklatvala J,. Basic fibroblast growth factor mediates transduction of mechanical signals when articular cartilage is loaded. Arthritis Rheum 2004; 50: 526-33.
28. Saksela O, Moscatelli D, Sommer A, Rifkin DB,. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 1988; 107: 743-51.
29. Flaumenhaft R, Moscatelli D, Saksela O, Rifkin DB,. Role of extracellular matrix in the action of basic fibroblast growth factor: matrix as a source of growth factor for long-term stimulation of plasminogen activator production and DNA synthesis. J Cell Physiol 1989; 140: 75-81.
30. Tokunou T, Miller R, Patwari P, Davis ME, Segers VF, Grodzinsky AJ, et al. Engineering insulin-like growth factor-1 for local delivery. FASEB J 2008; 22: 1886-93.
31. Cardin AD, Weintraub HJ,. Molecular modeling of protein-glycosaminoglycan interactions. Arterioscler Thromb Vasc Biol 1989; 9: 21-32.
32. Thompson SA, Higashiyama S, Wood K, Pollitt NS, Damm D, McEnroe G, et al. Characterization of sequences within heparin-binding EGF-like growth factor that mediates interaction with heparin. J Biol Chem 1994; 269: 2541-9.
33. Oike Y, Kimata K, Shinomura T, Nakazawa K, Suzuki S,. Structural analysis of chick-embryo cartilage proteoglycan by selective degradation with chondroitin lyases (chondroitinases) and endo-β-D-galactosidase (keratanase). Biochem J 1980; 191: 193-207.
34. Silverberg I, Havsmark B, Fransson LA,. The substrate specificity of heparan sulphate lyase and heparin lyase from Flavobacterium heparinum. Carbohydr Res 1985; 137: 227-38.
35. David G, Bai XM, van der Schueren B, Cassiman JJ, van den Berghe H,. Developmental changes in heparan sulfate expression: in situ detection with mAbs. J Cell Biol 1992; 119: 961-75.
36. Lidholt K, Weinke JL, Kiser CS, Lugemwa FN, Bame KJ, Cheifetz S, et al. A single mutation affects both N-acetylglucosaminyltransferase and glucuronosyltransferase activities in a Chinese hamster ovary cell mutant defective in heparan sulfate biosynthesis. Proc Natl Acad Sci U S A 1992; 89: 2267-71.
37. Ley K, Cerrito M, Arfors KE,. Sulfated polysaccharides inhibit leukocyte rolling in rabbit mesentery venules. Am J Physiol 1991; 260: H1667-73.
38. Friedrich U, Blom AM, Dahlback B, Villoutreix BO,. Structural and energetic characteristics of the heparin-binding site in antithrombotic protein C. J Biol Chem 2001; 276: 24122-8.
39. Ricard-Blum S, Feraud O, Lortat-Jacob H, Rencurosi A, Fukai N, Dkhissi F, et al. Characterization of endostatin binding to heparin and heparan sulfate by surface plasmon resonance and molecular modeling: role of divalent cations. J Biol Chem 2004; 279: 2927-36.
40. Muehleman C, Bareither D, Huch K, Cole AA, Kuettner KE,. Prevalence of degenerative morphological changes in the joints of the lower extremity. Osteoarthritis Cartilage 1997; 5: 23-37.
41. Collins DH,. The pathology of articular and spinal diseases. London: Edward Arnold; 1949. p. 76-9.
42. Sui Y, Lee JH, DiMicco MA, Vanderploeg EJ, Blake SM, Hung HH, et al. Mechanical injury potentiates proteoglycan catabolism induced by interleukin-6 with soluble interleukin-6 receptor and tumor necrosis factor α in immature bovine and adult human articular cartilage. Arthritis Rheum 2009; 60: 2985-96.
43. Govindraj P, West L, Koob TJ, Neame P, Doege K, Hassell JR,. Isolation and identification of the major heparan sulfate proteoglycans in the developing bovine rib growth plate. J Biol Chem 2002; 277: 19461-9.
44. Raman R, Venkataraman G, Ernst S, Sasisekharan V, Sasisekharan R,. Structural specificity of heparin binding in the fibroblast growth factor family of proteins. Proc Natl Acad Sci U S A 2003; 100: 2357-62.
45. Garcia AM, Szasz N, Trippel SB, Morales TI, Grodzinsky AJ, Frank EH,. Transport and binding of insulin-like growth factor I through articular cartilage. Arch Biochem Biophys 2003; 415: 69-79.
46. Bhakta NR, Garcia AM, Frank EH, Grodzinsky AJ, Morales TI,. The insulin-like growth factors (IGFs) I and II bind to articular cartilage via the IGF-binding proteins. J Biol Chem 2000; 275: 5860-6.
47. Martel-Pelletier J, Di Battista JA, Lajeunesse D, Pelletier JP,. IGF/IGFBP axis in cartilage and bone in osteoarthritis pathogenesis. Inflamm Res 1998; 47: 90-100.
48. Martin JA, Ellerbroek SM, Buckwalter JA,. Age-related decline in chondrocyte response to insulin-like growth factor-I: the role of growth factor binding proteins. J Orthop Res 1997; 15: 491-8.
49. Loeser RF, Shanker G, Carlson CS, Gardin JF, Shelton BJ, Sonntag WE,. Reduction in the chondrocyte response to insulin-like growth factor 1 in aging and osteoarthritis: studies in a non-human primate model of naturally occurring disease. Arthritis Rheum 2000; 43: 2110-20.
50. Dore S, Pelletier JP, DiBattista JA, Tardif G, Brazeau P, Martel-Pelletier J,. Human osteoarthritic chondrocytes possess an increased number of insulin-like growth factor 1 binding sites but are unresponsive to its stimulation: possible role of IGF-1-binding proteins. Arthritis Rheum 1994; 37: 253-63.
51. Bagley CJ, May BL, Szabo L, McNamara PJ, Ross M, Francis GL, et al. A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide. Biochem J 1989; 259: 665-71.